<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Family Doctor</journal-id><journal-title-group><journal-title xml:lang="en">Russian Family Doctor</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский семейный врач</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-1668</issn><issn publication-format="electronic">2713-2331</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">217717</article-id><article-id pub-id-type="doi">10.17816/RFD217717</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case report</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинический случай</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modification of the course of post-COVID syndrome associated with reactivation of chronic persistent Epstein−Barr virus infection and chronic nasopharyngotonsillitis of mixed etiology</article-title><trans-title-group xml:lang="ru"><trans-title>Модификация течения постковидного синдрома, ассоциированная с реактивацией хронической персистирующей Эпштейна – Барр-вирусной инфекции и обострением хронического ринофаринготонзиллита смешанной этиологии</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-7951-5508</contrib-id><contrib-id contrib-id-type="spin">1798-2618</contrib-id><name-alternatives><name xml:lang="en"><surname>Neverov</surname><given-names>Vladimir A.</given-names></name><name xml:lang="ru"><surname>Неверов</surname><given-names>Владимир Александрович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>v.neveroff@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">North-Western State Medical University named after I.I. Mechnikov</institution></aff><aff><institution xml:lang="ru">Северо-Западный государственный медицинский университет им. И.И. Мечникова</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-02-22" publication-format="electronic"><day>22</day><month>02</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-04-10" publication-format="electronic"><day>10</day><month>04</month><year>2023</year></pub-date><volume>27</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>51</fpage><lpage>56</lpage><history><date date-type="received" iso-8601-date="2023-02-11"><day>11</day><month>02</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-02-22"><day>22</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2023,</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-04-10"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/RFD/article/view/217717">https://journals.eco-vector.com/RFD/article/view/217717</self-uri><abstract xml:lang="en"><p>A wide range of symptoms that occur in patients with post-COVID syndrome can include both manifestations of the clinical consequences of COVID-19 and symptoms of an exacerbation of a chronic pathology that they had before the development of coronavirus infection. Correct assessment of clinical data can help determine the origin of the existing manifestations of the disease and build a plan for adequate diagnostic and therapeutic measures.</p> <p>In the article, on the example of a clinical case, a variant of the modified (exacerbation of chronic pathology) course of the post-COVID syndrome was analyzed. An example of modern laboratory diagnostics of reactivation of chronic persistent Epstein–Barr virus infection and exacerbation of chronic nasopharyngotonsillitis of mixed viral-bacterial-mycotic etiology, developed against the background of post-COVID syndrome, is given. The principles of therapy for this comorbid condition are presented and explained.</p></abstract><trans-abstract xml:lang="ru"><p>Большой спектр симптомов, возникающих у пациентов с постковидным синдромом, может включать проявления как клинической картины последствий COVID-19, так и обострения хронической патологии, существовавшей до развития коронавирусной инфекции. Правильная оценка клинических данных может помочь определить происхождение проявлений заболевания и выстроить план адекватных диагностических и лечебных мероприятий.</p> <p>В статье на примере клинического случая разобран вариант модифицированного (обострением хронической патологии) течения постковидного синдрома. Дан пример современной лабораторной диагностики реактивации хронической персистирующей Эпштейна – Барр-вирусной инфекции и обострения хронического ринофаринготонзиллита смешанной вирусно-бактериально-микотической этиологии, развившихся на фоне постковидного синдрома. Представлены и объяснены принципы терапии этого коморбидного состояния.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>post-COVID syndrome</kwd><kwd>Epstein–Barr virus infection</kwd><kwd>chronic nasopharyngotonsillitis</kwd><kwd>coronovirus infection</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>постковидный синдром</kwd><kwd>Эпштейна – Барр-вирусная инфекция</kwd><kwd>хронический ринофаринготонзиллит</kwd><kwd>коронавирусная инфекция</kwd><kwd>SARS-CoV-2</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Belotserkovskaya YuG, Romanovskikh AG, Smirnov IP, et al. Long COVID-19. Consilium Medicum. 2021;23(3):261–268. (In Russ.). DOI: 10.26442/20751753.2021.3.200805</mixed-citation><mixed-citation xml:lang="ru">Белоцерковская Ю.Г., Романовских А.Г., Смирнов И.П. и др. Долгий COVID-19 // Consilium Medicum. 2021. Т. 23, № 3. С. 261–268. DOI: 10.26442/20751753.2021.3.200805</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Khasanova DR, Zhitkova YuV, Vaskaeva GR. Postcovid syndrome: a review of knowledge about the pathogenesis, neuropsychiatric manifestations and treatment prospects. Neurology, neuropsychiatry, psychosomatics. 2021;13(3):93–98. (In Russ.). DOI: 10.14412/2074-27112021-3-93-98</mixed-citation><mixed-citation xml:lang="ru">Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения // Неврология, нейропсихиатрия, психосоматика. 2021. Т. 13, № 3. С. 93–98. DOI: 10.14412/2074-27112021-3-93-98</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Amirov NB, Davletshina EI, Vasilyeva AG, Fatykhov RG. Postcovid syndrome: multisystem “deficiencies”. Bulletin of modern clinical medicine. 2021;14(6):94–104. (In Russ.). DOI: 10.20969/VSKM.2021.14(6).94-104</mixed-citation><mixed-citation xml:lang="ru">Амиров Н.Б., Давлетшина Э.И., Васильева А.Г., Фатыхов Р.Г. Постковидный синдром: мультисистемные «дефициты» // Вестник современной клинической медицины. 2021. Т. 14, № 6. С. 94–104. DOI: 10.20969/VSKM.2021.14(6).94-104</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Metodicheskie rekomendatsii “Osobennosti techeniya long-COVID infektsii. Terapevticheskie i reabilitatsionnye meropriyatiya”. 217 p. [Internet]. Available from: https://irk-gb6.ru/images/uploads/c0c122cdc473c3b9968cce024a0ccdac.pdf. Accessed: 02.09.2023. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Методические рекомендации «Особенности течения long-COVID инфекции. Терапевтические и реабилитационные мероприятия». 217 с. [Электронный ресурс]. Режим доступа: https://irk-gb6.ru/images/uploads/c0c122cdc473c3b9968cce024a0ccdac.pdf. Дата обращения: 09.02.2023.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. Available from: https://www.nice.org.uk/guidance/ng188. Accessed: 31.08.2021.</mixed-citation><mixed-citation xml:lang="ru">COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Электронный ресурс]. Режим доступа: https://www.nice.org.uk/guidance/ng188. Дата обращения: 31.08.2021.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Diaz JV, Soriano JB. A Delphi consensus to advance on a clinical case definition for post COVID-19 condition: a WHO protocol. Protocol Exchange. 2021. DOI: 10.21203/rs.3.pex-1480/v1</mixed-citation><mixed-citation xml:lang="ru">Diaz J.V., Soriano J.B. A Delphi consensus to advance on a clinical case definition for post COVID-19 condition: a WHO protocol // Protocol Exchange. 2021. DOI: 10.21203/rs.3.pex-1480/v1</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Kabi A, Mohanty A, Mohanty AP, Kumar S. Post COVID-19 syndrome: a literature review. JAMMR. 2020;32(24):289–295. DOI: 0.9734/jammr/2020/v32i2430781</mixed-citation><mixed-citation xml:lang="ru">Kabi A., Mohanty A., Mohanty A.P., Kumar S. Post COVID-19 syndrome: a literature review // JAMMR. 2020. Vol. 32, No. 24. P. 289–295. DOI: 10.9734/jammr/2020/v32i2430781</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. DOI: 10.1038/s41591-021-01283-z</mixed-citation><mixed-citation xml:lang="ru">Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome // Nat. Med. 2021. Vol. 27, No. 4. P. 601–615. DOI: 10.1038/s41591-021-01283-z</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Perrin R, Riste L, Hann M, et al. Into the looking glass: Post-viral syndrome post COVID-19. Med hypotheses. 2020;144:110055. DOI: 10.1016/j.mehy.2020.110055</mixed-citation><mixed-citation xml:lang="ru">Perrin R., Riste L., Hann M. et al. Into the looking glass: Post-viral syndrome post COVID-19 // Med. Hypotheses. 2020. Vol. 144. P. 110055. DOI: 10.1016/j.mehy.2020.110055</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Long COVID or Post-COVID Conditions. CDC, 2021 [Internet]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed: 18.07.2021.</mixed-citation><mixed-citation xml:lang="ru">Long COVID or Post-COVID Conditions. CDC 2021 [Электронный ресурс]. Режим доступа: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Дата обращения: 18.07.2021.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">van Kampen JJA, van de Vijver DAMC, Fraaij PLA et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat. Commun. 2021. Vol. 267, No. 12. P. 1–6. DOI: 10.1038/s41467-020-20568-4</mixed-citation><mixed-citation xml:lang="ru">van Kampen J.J.A., van de Vijver D.A.M.C., Fraaij P.L.A. et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) // Nat. Commun. 2021. Vol. 267, No. 12. P. 1–6. DOI: 10.1038/s41467-020-20568-4</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Marx V. Scientists set out to connect the dots on long COVID. Nat Methods. 2021;18(5):449–453. DOI: 10.1038/s41592-021-01145-z13</mixed-citation><mixed-citation xml:lang="ru">Marx V. Scientists set out to connect the dots on long COVID // Nat. Methods. 2021. Vol. 18, No. 5. P. 449–453. DOI: 10.1038/s41592-021-01145-z</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Avanzato VA, Matson MJ, Seifert SN, et al. Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient. Cell. 2020;183(7):1901–1912. DOI: 10.1016/j.cell.2020.10.049</mixed-citation><mixed-citation xml:lang="ru">Avanzato V.A., Matson M.J., Seifert S.N. et al. Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient // Cell. 2020. Vol. 183, No. 7. P. 1901–1912. DOI: 10.1016/j.cell.2020.10.049</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(22):2291–2293. DOI: 10.1056/NEJMc2031364</mixed-citation><mixed-citation xml:lang="ru">Choi B., Choudhary M.C., Regan J. et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host // N. Engl. J. Med. 2020. Vol. 383, No. 22. P. 2291–2293. DOI: 10.1056/NEJMc2031364</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Nagasaki Y, Kadowaki M, Nakamura A, et al. A case of a malignant lymphoma patient persistently infected with SARS-CoV-2 for more than 6 months. Medicina (Kaunas). 2023;59(1):108. DOI: 10.3390/medicina59010108</mixed-citation><mixed-citation xml:lang="ru">Nagasaki Y., Kadowaki M., Nakamura A. et al. A case of a malignant lymphoma patient persistently infected with SARS-CoV-2 for more than 6 months // Medicina (Kaunas). 2023. Vol. 59, No. 1. P. 108. DOI: 10.3390/medicina59010108</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Camprubí D, Gaya A, Marcos MA, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379–381. DOI: 10.1016/j.ijid.2020.12.050</mixed-citation><mixed-citation xml:lang="ru">Camprubí D., Gaya A., Marcos M.A. et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir // Int. J. Infect. Dis. 2021. Vol. 104. P. 379–381. DOI: 10.1016/j.ijid.2020.12.050</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):1103–1107. DOI: 10.1093/infdis/jiaa446</mixed-citation><mixed-citation xml:lang="ru">Helleberg M., Niemann C.U., Moestrup K.S. et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy // J. Infect. Dis. 2020. Vol. 222, No. 7. P. 1103–1107. DOI: 10.1093/infdis/jiaa446</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma. Am J Case Rep. 2020;21:e927812. DOI: 10.12659/AJCR.927812</mixed-citation><mixed-citation xml:lang="ru">Moore J.L., Ganapathiraju P.V., Kurtz C.P., Wainscoat B. A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma // Am. J. Case Rep. 2020. Vol. 21. P. e927812. DOI: 10.12659/AJCR.927812</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993–998. DOI: 10.15585/mmwr.mm6930e1</mixed-citation><mixed-citation xml:lang="ru">Tenforde M.W., Kim S.S., Lindsell C.J. et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020 // MMWR. Morb. Mortal. Wkly. Rep. 2020. Vol. 69, No. 30. P. 993–998. DOI: 10.15585/mmwr.mm6930e1</mixed-citation></citation-alternatives></ref></ref-list></back></article>
